Free Content Increased bone resorption in patients with Crohn's disease

Authors: Robinson1; Iqbal2; Abrams3; Al-Azzawi4; Mayberry1

Source: Alimentary Pharmacology & Therapeutics, Volume 12, Number 8, August 1998 , pp. 699-705(7)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background:

Patients with Crohn's disease are at risk of osteoporosis and premature fracture. However, the pathophysiology underlying bone loss remains poorly understood and the optimum treatment has not been established. Aim:

To investigate mechanisms of bone loss in Crohn's disease using biochemical markers of bone turnover. Methods:

Bone mineral density was measured at the hip and spine using dual-energy X-ray absorptiometry in 117 patients (48 male) with Crohn's disease. Bone turnover was assessed by measuring serum osteocalcin (BGP), pro-collagen carboxy-terminal propeptide (PICP), bone specific alkaline phosphatase (BALP) and urinary deoxypyridinoline (DPD); and compared to age-matched healthy controls (n = 28). Results:

Bone mineral density was reduced (z-score < −1) in 48 (41%) patients with Crohn's disease. Mean values for bone formation markers in patients with Crohn's disease were all within the normal reference range (BGP 8.92 (± 3.23) ng/mL (normal range 3.4-10.0), BALP 17.6 (±12.6) U/L (normal range 11.6-43.3), PICP 95.1 (± 46.5) ng/mL (normal range 69-163)) and were not significantly different to the control population. However, mean urinary DPD was significantly higher in patients with Crohn's disease compared to healthy controls (10.97 (±9.22) nM DPD/mM creatinine vs. 5.02 (±1.03) nM DPD/mM creatinine, difference in means = 5.95, 95% CI: −9.6 to −2.3, P = 0.00001) and compared to the UK reference range DPD levels were increased in 74 (63%) patients. Conclusions:

Bone resorption as evidenced by urinary DPD was frequently increased in patients with Crohn's disease and was significantly higher than in an age-matched control population. The high levels of urinary DPD suggest increased bone collagen degradation may contribute to osteoporosis in patients with Crohn's disease. These results suggest anti-resorptive agents such as the bisphosphonates may be effective treatment for osteoporosis in Crohn's disease.

Document Type: Original article

DOI: 10.1046/j.1365-2036.1998.00364.x

Affiliations: 1: Gastrointestinal Research Unit, Leicester General Hospital, 2: Department of Clinical Chemistry, Leicester Royal Infirmary, 3: Department of Epidemiology and Public Health, University of Leicester, 4: Department of Obstetrics & Gynaecology, Leicester Royal Infirmary, Leicester, UK

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A